Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lisdexamfetamine Capsule vs Elvanse in Healthy Adults
NCT07098585Phase 1Completed
- Sponsor
- Humanis
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Humanis. Primary endpoints: Maximum measured plasma concentration at 72 hours and Area under the plasma concentration versus time curve from zero to last quantifiable concentration at 72 hours. Started May 2025; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07098585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098585.